Kailera Therapeutics is trading at $12.05, down 6.73% in pre-market as broad risk-off sentiment pressures stocks. - On October 22, 2026, concerns about AI spending and rising oil prices weighed on markets. - Reuters reported Nasdaq futures down more than 1% and Brent crude near $112. - The biotech-sector trend is positive; the KL-279 trial launch is not a clear explanation, and no company-specific cause was identified.